PERSPECTIVES ON THE IN VITRO EVALUATION OF ANTI-ANAPHYLACTIC AGENTSWEINRYB I; COUTTS SM; KHANDWALA AS et al.1983; DRUG DEVELOPMENT RESEARCH; ISSN 0272-4391; USA; DA. 1983; VOL. 3; NO 3; PP. 213-219; BIBL. 3 P.Article

SYNTHESIS AND CENTRAL NERVOUS SYSTEM ACTIVITY OF 2-ARYLIDENE-4-AMINOALKYL-2H-1,4-BENZOXAZIN-3(4H)-ONES AND RELATED COMPOUNDS.TURK CF; KRAPCHO J; MICHEL IM et al.1977; J. MEDICIN. CHEM.; U.S.A.; DA. 1977; VOL. 20; NO 5; PP. 729-732; BIBL. 7 REF.Article

DIHYDRO- AND TETRAHYDROISOQUINOLINES AS INHIBITORS OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES FROM DOG HEARTVAN INWEGEN RG; SALAMAN P; ST GEORGIEV V et al.1979; BIOCHEM. PHARMACOL.; GBR; DA. 1979; VOL. 28; NO 8; PP. 1307-1312; BIBL. 32 REF.Article

REV 2871 (CHBZ): a potent antiallergic agent with a novel mechanism of action. II: Studies on the mechanism of actionCOUTTS, S. M; ATUL KHANDWALA; WEINRYB, I et al.Biochemical pharmacology. 1987, Vol 36, Num 5, pp 673-682, issn 0006-2952Article

THE PHARMACODYNAMICS OF BUCAINIDE (RHC G233): PHARMACOKINETIC PARAMETERS AND RELATIONSHIP BETWEEN PLASMA LEVELS AND THE EFFECT ON THE ELECTROCARDIOGRAM IN THE DOGGREBOW P; FEENEY W; JOHNSTON M et al.1981; RES. COMMUN. CHEM. PATHOL. PHARMACOL.; ISSN 0034-5164; USA; DA. 1981; VOL. 32; NO 3; PP. 407-421; BIBL. 12 REF.Article

REV 2871 (CHBZ): a potent antiallergic agent with a novel mechanism of action. I: Activity profile as an inhibitor of mediator releaseATUL KHANDWALA; COUTTS, S; PRUSS, T et al.Biochemical pharmacology. 1987, Vol 36, Num 5, pp 663-672, issn 0006-2952Article

RHC 3288 [1-methyl-2(1,3,4-oxadiazol-2(3H)-one-5-yl) benzimidazole] and related compounds: novel inhibitors of histamine release from rat mast cells and human basophilsKHANDWALA, A; COUTTS, S; DALLY-MEADE, V et al.Biochemical pharmacology. 1983, Vol 32, Num 22, pp 3325-3333, issn 0006-2952Article

Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysisVAN INWEGEN, R. G; KHANDWALA, A; WEINRYB, I et al.Archives internationales de pharmacodynamie et de thérapie. 1984, Vol 272, Num 1, pp 40-55, issn 0003-9780Article

A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertensionANDRAWIS, N. S; BATTLE, M. M; KLAMERUS, K. J et al.Journal of clinical pharmacology. 2000, Vol 40, Num 3, pp 231-241, issn 0091-2700Article

Antiallergic activity profiles in vitro of RHC 3164 and related compounds. I: A lack of correlation between inhibition of cyclic nucleotide phosphodiesterases and antigen-induced release of histamine from rat mast cellsKHAMDWALA, A; VAN INWEGEN, R; COUTTS, S et al.International archives of allergy and applied immunology. 1984, Vol 73, Num 1, pp 56-64, issn 0020-5915Article

Substituted arylmethyl phenyl ethers. I: A novel series of 5-lipoxygenase inhibitors and leukotriene antagonistsMUSSER, J. H; CHAKRABORTY, U. R; SCIORTINO, S et al.Journal of medicinal chemistry (Print). 1987, Vol 30, Num 1, pp 96-104, issn 0022-2623Article

Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio) alkanoyl] glycine derivativesSUH, J. T; SKILES, J. W; WOLF, P. S et al.Journal of medicinal chemistry (Print). 1985, Vol 28, Num 1, pp 57-66, issn 0022-2623Article